Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. - Wikidata - awgldk - TriplyDB

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

http://www.wikidata.org/entity/Q35044909

about

Selection Criteria and Current Issues in Liver Transplantation for Hepatocellular Carcinoma Asunaprevir Recent Advances in Antiviral Therapy for Chronic Hepatitis C KASL clinical practice guidelines: management of hepatitis C Daclatasvir Sofosbuvir treatment and hepatitis C virus infection Update on hepatitis C: Direct-acting antivirals Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients New era for management of chronic hepatitis C virus using direct antiviral agents: A review Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection Surgical approach for hepatitis C virus-related hepatocellular carcinoma Antiviral therapies for chronic hepatitis C virus infection with cirrhosis Approved Antiviral Drugs over the Past 50 Years A Review of Daclatasvir Drug-Drug Interactions Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis Interferon-free combination therapies for the treatment of hepatitis C: current insights A 2015 roadmap for the management of hepatitis C virus infections in Asia Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.A Case Report of Drug-Induced Thrombocytopenia after Living Donor Liver Transplantation.Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors.Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Successes and Challenges on the Road to Cure Hepatitis C Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study.Natural interferon-beta treatment for patients with chronic hepatitis C in Japan Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.

P2860

Q26744102-93225E68-1074-49F9-9BB1-A902F8893519 Q26747354-D3F39801-D659-47B7-83BA-77A2249A6D6B Q26750476-45AA373C-653B-41B3-A5F9-1793C19ECAE5 Q26752471-76B998FD-582F-4B69-B293-567B6573B943 Q26769624-1B074FEE-335B-4FB3-BAB3-954446765C5F Q26770024-EB3AFC88-2507-4054-8012-56AE1B1EE22C Q26775809-2DB56880-A709-414B-8F4B-5DF9D6B5D74E Q26777659-E44F3974-19B1-4456-8250-2C253F166C44 Q26782405-C10655D0-1D2C-4D0C-9153-8A161CF58D33 Q26795595-6DA76E75-DE43-4419-9350-9B0AEED24BA4 Q26800050-22D5F0E4-BEAC-4571-9990-B73CE0D9FFCF Q26801381-3E026A15-9E13-4A6E-AB1A-37FE96ADE5A0 Q26824046-CFDADB51-5E5F-4E87-A3DE-2F1AD57A6F6F Q27022794-5D09B864-0B2B-4ECA-9CDF-0DF3E4770703 Q27755387-644A35D7-505F-4826-BFAA-1C7BCD85686A Q28068712-FF8D318C-21BD-4776-B085-0776E8315AF2 Q28070260-5C5B012F-2983-4037-A42D-047E8176E466 Q28077287-87502EB2-B6E6-4556-AA62-379834137182 Q28087400-23B12F19-7679-4F1E-B8A1-ED1994EE2417 Q28088762-2BB5F6FF-0CDC-48D1-865A-3169B9646949 Q28548426-E681916C-DE6B-493A-BB98-1FE24529D6D1 Q30402571-86360EFA-8893-4DB6-9C10-5953C6D8B697 Q30843427-9E4E2439-B2B3-4176-A221-44FE859233AD Q31170657-C9623A00-6B1D-4707-905C-7A587D6FFDD4 Q33434355-C9751C6F-9072-404F-9293-BF3BAADCB882 Q33576524-B20A3E56-FB22-4D7B-997D-D0C1D06EB6B0 Q33582978-ED55C223-3A2D-40D0-9845-910B882D2C7F Q33710278-23363F6B-FF39-42D6-9D8A-F6B725F22DCB Q34040906-596F30E3-0BFC-42D8-B598-3DE16AFF270D Q34332546-20BB4454-90F6-410E-BD71-1F9A8E08C633 Q34513827-F57348A6-8C12-4ADC-903E-23891B930861 Q34522481-CA722D22-BF45-4EF8-8006-B050F04D73B1 Q35667588-7D609CC3-DCE5-4C7B-8E48-DE2C9CE4776C Q35667907-2882ACAB-0A98-4BA9-B45F-FE3DFE3F6FD6 Q35668734-D916D7FE-FB9C-40CE-B01C-BB902E8D57FE Q35774186-7CD3FAB0-EB4A-4CAA-BD54-7D94E0408CAA Q35907984-10364F37-56F7-49CD-B47C-B07C903236A8 Q35947900-639F250B-8187-41AA-A1A6-001A2921F83D Q35962458-A1C5B821-82E8-41B6-951E-58417490E323 Q35968616-E4AB28BC-D87F-4080-A2DF-DDC93AA0CEA4

P2860

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

http://www.wikidata.org/entity/Q35044909

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

@en

type

label

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

@en

prefLabel

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

@en

P1433

Q35044909-BB7708CE-5204-4AD3-94DD-527A75874D73

P1476

Q35044909-CE9E9E15-37E7-42FE-8DEB-8E61F0AE1275

P2093

Q35044909-18EDD3A5-BE1C-4606-97B1-5C16D5EFAFEA

Q35044909-3AAA256A-9545-4ACB-945F-BB59F47540EC

Q35044909-3FD6E4FF-88A7-4227-B500-CA1118E9E329

Q35044909-41329C64-3F68-4B13-A150-1F4488571DF7

Q35044909-5267AD85-F321-4C17-A5DE-0A5E0E02EB74

Q35044909-56298284-493A-4137-B886-5DEC90A9B300

Q35044909-7974CEBD-244E-4A00-A622-0733AF60BD24

Q35044909-7EF43601-B682-42B7-8B6B-571084CE8C40

Q35044909-8A8E1447-FCD8-469C-B12D-778D09E419A2

Q35044909-A1EE6BDD-93D3-4DCC-BFB5-B0ACE2BFC936

P2860

Q35044909-263CBE43-F5CB-442D-BFF6-28EC4652851A

Q35044909-265A337B-C3E6-48FF-9E3F-91A5D8502413

Q35044909-2894BE4A-2758-4DD1-BB45-F77D3DE57673

Q35044909-294F8FA1-3E7C-4A27-B80A-DC68B4FCE2D7

Q35044909-38C6EC3E-37F3-4DB6-91DF-89E53F8ED474

Q35044909-3A58C9FF-54ED-4A8B-801B-A40681ADB615

Q35044909-48E3A294-973B-4C03-AA2B-E1EF64BC23F5

Q35044909-53B3957B-1254-4792-A061-7659EBB5A258

Q35044909-55BAB073-35FF-40CF-B50E-27467A9A8C54

Q35044909-5D2E5133-CCD7-4DB8-BF1D-7A58AA335095

P304

Q35044909-C91901C1-A317-4C41-969F-D391D051A5FD

P31

Q35044909-6106259D-4108-45E7-BFC1-F0B097AAA522

P356

Q35044909-31B344DD-0FBB-4082-B175-A4A889057521

P407

Q35044909-D0BC7A4D-85B3-4079-A5FC-2AA6F58D4D99

P433

Q35044909-8D47A08D-1B71-4FC3-B2E9-F0B1500DA94C

P478

Q35044909-86D22015-1CAB-41BA-87E2-975E34AC0D1D

P50

Q35044909-A6889EBC-C77E-4743-8397-43B5EF811189

P577

Q35044909-1227B90D-AE23-4A36-8EF0-420F70AF05BA

P5875

Q35044909-BED47880-CAFB-46AA-8149-C876B58D4A96

P698

Q35044909-5E50DB85-00BD-4939-B24D-2BC6F7721918

P932

Q35044909-EFEDC2B1-3CCB-4EB1-A994-75430611C8DF

P356

P1433

P1476

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

@en

P2093

Akio Ido

http://www.w3.org/2001/XMLSchema#string

Andrew Damokosh

http://www.w3.org/2001/XMLSchema#string

Eric Hughes

http://www.w3.org/2001/XMLSchema#string

Fiona McPhee

http://www.w3.org/2001/XMLSchema#string

Hidetaka Miyagoshi

http://www.w3.org/2001/XMLSchema#string

Hiroki Ishikawa

http://www.w3.org/2001/XMLSchema#string

Hiromitsu Kumada

http://www.w3.org/2001/XMLSchema#string

Joji Toyota

http://www.w3.org/2001/XMLSchema#string

Kazuaki Chayama

http://www.w3.org/2001/XMLSchema#string

Kazuhide Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

Telaprevir for retreatment of HCV infection

Telaprevir for previously untreated chronic hepatitis C virus infection

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

Boceprevir for untreated chronic HCV genotype 1 infection

Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data.

Preliminary study of two antiviral agents for hepatitis C genotype 1.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

P304

2083-2091

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.27113

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260611671

http://www.w3.org/2001/XMLSchema#string

P698

24604476

http://www.w3.org/2001/XMLSchema#string

P932

4315868

http://www.w3.org/2001/XMLSchema#string